New thyroid receptor ligands are provided which have the general formula I ##STR1##

    • wherein
    • R1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted C3-7 cycloalkyl;
    • R2 and R3 are each independently hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted C3-6 cycloalkyl, wherein at least one of R2 and R3 is other than hydrogen;
    • R4 is a carboxylic acid selected from the group consisting of (CH2)nCOOH, (CH)2COOH, NHCO(CH2)nCOOH, CONH(CH2)nCOOH and NH(CH2)mCOOH;
    • n is an integer from 0 to 4; and
    • m is an integer from 1 to 4.
    • In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

     
    Web www.patentalert.com

    < Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents

    < Secreted and transmembrane polypeptides and nucleic acids encoding the same

    > Dipeptide derivatives

    > Pyrrolotriazine kinase inhibitors
    ~ 00212